Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | CXCR4 | P61073 | 11/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.34 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26665904 | 0.74 | SIGMAR1 (0.55) | SIGMAR1CXCR4MEN1CHRM2CHRM1 | |
| SCHEMBL21851189 | 0.73 | KDR (0.39) | SIGMAR1CXCR4MEN1CHRM2CHRM1 | |
| SCHEMBL19490798 | 0.72 | SIGMAR1 (0.56) | SIGMAR1CXCR4MEN1CHRM2CHRM1 | |
| SCHEMBL13937097 | 0.72 | SIGMAR1 (0.52) | SIGMAR1CXCR4MEN1CHRM2CHRM1 | |
| SCHEMBL14606249 | 0.72 | SIGMAR1 (0.52) | SIGMAR1CXCR4MEN1CHRM2CHRM1 | |
| SCHEMBL21850871 | 0.71 | KCNJ1 (0.49) | SIGMAR1CXCR4MEN1CHRM2CHRM1 | |
| SCHEMBL21850849 | 0.71 | SIGMAR1 (0.44) | SIGMAR1CXCR4MEN1CHRM2CHRM1 | |
| SCHEMBL21850800 | 0.70 | KCNJ1 (0.51) | SIGMAR1CXCR4MEN1CHRM2CHRM1 | |
| SCHEMBL25177979 | 0.70 | TAAR1 (0.55) | SIGMAR1CXCR4MEN1CHRM2CHRM1 | |
| SCHEMBL24135334 | 0.69 | KDR (0.40) | SIGMAR1CXCR4MEN1CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3929194-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | Bristol-Myers Squibb Company (US) | 2021-12-29 | — | — | EP | disclosed |
| US-20200109135-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200109135-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | NR0B1, GRK1, GRIN1 | SIGMAR1 64/4885CXCR4 666/4885MEN1 1520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.